Metformin, Newer Oral Medications Linked to Better Cognitive Performance in T2D
Older men with type 2 diabetes who received metformin or newer hypoglycemic medication had less cognitive decline compared with those who received sulfonylureas.
All articles by Rachael Beairsto
FDA Commissioner Reaffirms Commitment to Lower Insulin Prices and Expand Access
Dr Gottlieb expressed that the FDA is committed to bringing competition to the insulin market to lower prices and expand patient access.
